GLP-1 Drugs and Adolescents: What's Approved and What Isn't
A small number of GLP-1 drugs carry adolescent approvals for obesity or diabetes. Here's which ones, and what the approval actually covers.
By the GLP Semaglutide editorial team · Last updated July 14, 2025
Wegovy holds FDA approval for chronic weight management in adolescents 12 and older with obesity, alongside its adult indication. Saxenda holds a similar adolescent obesity approval. Approval for adolescent use is drug-specific, not a category-wide green light.
Why age matters for approval
Pediatric and adolescent approvals require separate clinical trial data in that age group, which is why not every adult-approved GLP-1 drug has a corresponding adolescent indication, even within the same drug class.
A pediatric-specialist decision
Prescribing for adolescents typically involves a pediatric endocrinologist or obesity medicine specialist evaluating a broader clinical picture, not just a BMI number — this is a highly individualized decision outside the scope of general information.
Primary sources